Korro Bio, Inc.
NASDAQ Capital MarketTotal Valuation
Korro Bio, Inc. carries a market capitalization of 131.21M, placing it among publicly traded companies globally. Its enterprise value stands at 121.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 131.21M |
| Enterprise Value | 121.00M |
Share Statistics
Korro Bio, Inc. currently has 14.71M shares outstanding.
| Shares Outstanding | 14.71M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 71.21, and the price-to-book ratio stands at 1.88.
| PE Ratio | N/A |
| PS Ratio | 71.21 |
| PB Ratio | 1.88 |
| P/TBV Ratio | 1.88 |
| P/FCF Ratio | -2.51 |
| P/OCF Ratio | -2.50 |
Enterprise Valuation
| EV / Sales | 50.80 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Korro Bio, Inc. maintains a current ratio of 9.55, meaning it holds 9.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.55 |
| Quick Ratio | 9.11 |
| Debt / Equity | 40.89 |
| Debt / EBITDA | -0.58 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -97.69 |
| Return on Assets (ROA) | -62.03 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 839,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Korro Bio, Inc.'s stock has declined approximately -80.7767% over the past 52 weeks. The 50-day moving average sits at 11.59, while the 200-day moving average is 11.77.
| Beta (5Y) | N/A |
| 52-Week Price Change | -80.7767% |
| 50-Day Moving Average | 11.59 |
| 200-Day Moving Average | 11.77 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Korro Bio, Inc. generated 2.38M in revenue and converted that into -106.64M in net income, yielding earnings per share of -8.29. EBITDA reached -73.09M, while operating income came in at -75.67M.
| Revenue | 2.38M |
| Gross Profit | N/A |
| Operating Income | -75.67M |
| Pretax Income | -105.80M |
| Net Income | -106.64M |
| EBITDA | -73.09M |
| EBIT | -75.67M |
| Earnings Per Share (EPS) | -8.29 |
Balance Sheet
Korro Bio, Inc. holds 115.04M in cash and equivalents against 42.21M in total debt, resulting in a net debt position of -24.90M. Total book value stands at 103.23M, with working capital of 108.00M providing operational flexibility.
| Cash & Cash Equivalents | 115.04M |
| Total Debt | 42.21M |
| Net Debt | -24.90M |
| Equity (Book Value) | 103.23M |
| Book Value Per Share | 7.02 |
| Working Capital | 108.00M |
Cash Flow
Korro Bio, Inc. produced -67.95M in operating cash flow over the past twelve months. After subtracting -317,000.00 in capital expenditures, free cash flow totaled -68.26M - equivalent to -5.30 per share.
| Operating Cash Flow | -67.95M |
| Capital Expenditures | -317,000.00 |
| Free Cash Flow | -68.26M |
| FCF Per Share | -5.30 |
Margins
Korro Bio, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -3,176.57 and net profit margin of -4,477.08 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -3,176.57 |
| Pretax Margin | -4,441.86 |
| Profit Margin | -4,477.08 |
| EBITDA Margin | -3,068.56 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -44.27 |
| FCF Yield | -39.87 |
Stock Splits
Korro Bio, Inc.'s most recent stock split took place on November 6, 2023 with a 50:1 split ratio.
| Last Split Date | 11/6/2023 |
| Split Ratio | 50:1 |
Scores
Korro Bio, Inc. posts an Altman Z-Score of -2.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.41 |